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Background: We evaluated treatment modalities and survival in patients with hepatocellular carcinoma (HCC), by
pre-treatment and 3-month post-treatment serum alpha-fetoprotein (AFP) levels and pre-treatment tumor diameters.
Methods: We retrospectively reviewed 57 patients treated for HCC in our department from January 2002 to December
2012, including their sex, type of hepatitis, Child class, pre-treatment tumor size, pre-treatment levels of albumin,
aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), red blood cells,
hemoglobin, and total bilirubin, pre- and 3-month post-treatment serum AFP, and treatment modality (transarterial
chemoembolization, resection or radiofrequency ablation). Survival was analyzed at 1, 3, and 5 years after treatment.
Results: The 57 patients included 44 men and 13 women, of whom 44 had hepatitis C virus (HCV) infection, 3 had
hepatitis B virus (HBV) infection, 3 had both HBV and HCV infection, 1 had both HBV and hepatitis D virus infection,
and 3 had alcohol-related liver cirrhosis. Both pre- and post-treatment serum AFP levels significantly correlated with
recurrent tumor size (P < 0.05 for both). Pre-treatment tumor size did not correlate with recurrent tumor size.
Patients who underwent hepatic resection survived significantly longer than those who underwent transarterial
chemoembolization or radiofrequency ablation (P < 0.05).
Conclusions: Serum AFP level is useful in diagnosing tumor recurrence and predicting prognosis in HCC patients
treated by hepatic resection, transarterial chemoembolization, and radiofrequency ablation. Hepatic resection
remains the treatment of choice for HCC in suitable patients.
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Most primary liver cancers are hepatocellular carcinoma
(HCC), which is the third most common source of can-
cer fatalities worldwide. The main etiologies of HCC are
infection of the liver by hepatitis B virus (HBV) or hepa-
titis C virus (HCV), and alcohol abuse [1].
Alpha-fetoprotein (AFP) is an oncofetal protein pro-
duced by fetal hepatocytes, yolk-sac cells, and normal
gastrointestinal cells immediately after birth. Serum AFP
level decreases gradually after birth to <10 ng/mL within
300 days [2,3]. Normal adult serum AFP level is <20 ng/mL
[2]. Serum AFP level may be high in patients with drug or
alcohol abuse or with chronic liver disease such as hepa-
titis or cirrhosis, but in these cases, the level is usually
<100 ng/mL [4]. The Italian guidelines and the American
Association for the Study of Liver Diseases guidelines con-
sider serum AFP >200 ng/mL to be diagnostic for HCC
[2]. Some studies have suggested using a serum AFP
level of >400 ng/mL to diagnose HCC [5], or a solid
mass >2 cm in diameter with typical features of HCC on at
least one imaging study in a patient with liver cirrhosis [2].
High serum AFP levels occur in 60–70% of HCC pa-
tients; however, serum AFP levels remain in the normal
range in 15–30% of HCC patients [5]. AFP plays an im-
portant role in the regulation of both oncogenic and on-
togenetic growth [6]. Although early studies indicated
that AFP and its derived peptide fragments can inhibit
oncogenic growth [7], more recent studies have shown
that AFP can promote HCC cell growth. AFP+ HCC has
higher cell proliferative activity than AFP− HCC, as mea-
sured by the Ki-67 index [8]. Down-regulation of AFP
can suppress HCC cell growth [9]. High serum AFP level
correlates with more aggressive behavior and poorer prog-
nosis of HCC [2,10].
Serum AFP level has been suggested to directly reflect
tumor size, and the ratio of serum AFP level to tumor
diameter to predict recurrence after curative resection is
better than serum AFP alone [10]. To the best of our
knowledge, no reported studies evaluated whether the
relationship between pre- and post-treatment serum AFP
levels predict recurrent tumor size in HCC patients trea-
ted by hepatic resection (HR), transarterial chemoemboli-
zation (TACE), or radiofrequency ablation (RFA).
We evaluate relationships between treatment modality
(HR, TACE, and RFA) and survival in HCC patients, ac-
cording to pre-treatment and 3-month post-treatment
serum AFP levels and pre-treatment tumor diameter.
We also evaluated the relationships between 3-month
post-treatment serum AFP levels and recurrent tumor
size.
Methods
This retrospective study was approved by the local ethics
committee of Cannizzaro Hospital, Catania, Italy.From the patients who were treated for HCC in our
department from January 2002 to December 2012, we
included those aged > 18 years, with Child class A or B
HCC. Diagnosis of HCC and measurement of tumor
diameter were based on computed tomography (CT) or
magnetic resonance imaging findings. Data collected in-
cluded sex, age, type of hepatitis, Child class, tumor size,
pre-treatment tumor size, levels of albumin, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
gamma-glutamyltransferase (GGT), red blood cells, hemo-
globin, and total bilirubin, pre- and post-treatment serum
AFP levels, and treatment modality. Survival was analyzed
at 1, 3, and 5 years after treatment. Tumor size was de-
fined as maximum tumor diameter. If multiple tumors
were present, tumor size was defined as the sum of the
maximum diameters of all tumors.
All patients were followed up, with measurements of
serum AFP and CTs, every 3 months for the first year
after treatment, and then every 6 months for the next
4 years.
Patients were divided by their treatment modalities
into the HR group, the TACE group, and the RFA group.
Among patients who underwent HR, the selection cri-
teria were Child class A disease, and indocyanine green
retention rate at 15 min, as evaluated by the Makuuchi
algorithm [11]. Thus some patients with small HCCs
and negative results by the Makuuchi algorithm who re-
quested large resections were shifted to RFA or TACE
procedures. Resection types were defined according to the
Brisbane classification [12]. Curative resection was defined
as a 1-cm surgical margin of non-cancerous tissue on
postoperative histological examination.
Among patients who underwent TACE, selection cri-
teria were either Child class A or B disease with mul-
tiple tumors not suitable for surgery or RFA. The TACE
procedure involved cannulation of the femoral artery
using the Seldinger technique under local anesthesia. A
total of 50 mg of epirubicin emulsified in iodized oil was
used for chemotherapy; embolization was performed
using gelatin sponge particles. CT was performed 3
weeks after treatment to assess the results. All pa-
tients with hyperdense images related to the treated
tumors in basal CT scan were considered to have re-
ceived effective treatments.
Among patients who underwent RFA, selection criteria
were either Child class A or B disease with unique or
multiple nodules suitable for this technique. RFA was
performed under local anesthesia with sedation, using a
460-KHz generator. The electrode consisted of 9 hook-
shaped prongs (StarBurst XL; RITA Medical Systems,
Tyco Healthcare, Burlington, MA, USA), which can ab-
late a 5.0-cm diameter area. The entire tumor plus a
0.5–1.0-cm margin of surrounding normal hepatic tis-
sue was ablated. In the first CT scan after the treatment,
Figure 1 Survival of all patients after hepatic resection,
transarterial chemoembolization, and radiofrequency ablation.
Toro et al. BMC Surgery 2014, 14:40 Page 3 of 8
http://www.biomedcentral.com/1471-2482/14/40absence of arterial enhancement associate with ne-
crosis of the tumor was considered to signify effective
treatment.
Patients’ survival rates were analyzed and compared
according to treatment modality, pre-treatment serum
AFP level, 3-month post-treatment serum AFP level,
and pre-treatment tumor size.
Statistical analysis
Qualitative data were expressed as absolute frequency
and relative frequency. Quantitative data were expressed
as mean and standard deviation with minimum and max-
imum. Variables were calculated by Pearson’s r coefficient.
Survival was calculated using the Kaplan–Meier method,
and compared using the log-rank (Mantel–Cox) test.
P < 0.05 was considered significant.
Results
A total of 103 HCC patients were observed during the
study period, of whom 46 patients were excluded (27
were in Child class C and 19 who had no indication for
surgery refused to undergo RFA and TACE). Finally, 57
patients were included in the study, of whom 44 were
men (77.2%) and 13 were women (22.8%), aged 40–86
years (mean age: 68.5 ± 9.81 years; mean age for men:
68.8 ± 9.25 years; mean age for women: 67.2 ± 9.13 years);
25 had Child Class A disease and 32 had class B disease;
44 patients (77.2%) had HCV infection, 3 (5.3%) had
HBV infection, 3 (5.3%) had both HBV and HCV infec-
tion, and 1 (1.7%) had both HBV and hepatitis D virus
infection. All patients with hepatitis virus infection had
liver cirrhosis; 3 (5.3%) had alcohol-related cirrhosis, 1
(1.7%) had cryptogenic cirrhosis, and 2 (3.5%) had no
cirrhosis. Twenty patients (35.1%) underwent HR, 27
(47.4%) TACE, and 10 (17.5%) RFA.
Pre-treatment laboratory levels were mean albumin:
2.13 ± 0.53 g/dL, range: 1.84–5.13 g/dL (normal range
[NR]: 4.30–5.10 g/dL); mean AST: 77 ± 7.31 U/L, range:
17–217 U/L (NR: 8–39 U/L); mean ALT: 80.2 ± 10.3 U/L,
range: 9–244 U/L (NR: 9–52 U/L); mean GGT: 123.8 ±
8.24 U/L, range: 23–857 U/L (NR: 9–50 U/L); mean pro-
thrombin activity: 79.04 ± 5.37%, range: 43%–112% (NR:
70–140%); mean red cell count: 4.35 ± 1.23 M/L, range:
2.82–6.30 M/L (NR: 4.04–6.13 M/L); mean hemoglo-
bin: 12.4 ± 3.27 g/dL, range: 6.9–17.10 g/dL (NR: 12.2–
18.2 g/dL); mean total bilirubin: 1.13 ± 0.27 mg/dL, range:
0.01–2.76 mg/dL (NR: 0.2–1.3 mg/dL).
Mean pre-treatment serum AFP level was 211.52 ±
819.53 ng/mL, range: 1.30–6000.00 ng/mL (NR: 0–
20 ng/mL). Mean tumor size was 34.67 ± 22.52 mm,
range: 2.9–115 mm. Mean post-treatment serum AFP
level was 70.50 ± 122.17 ng/mL, range: 2.1–546 ng/mL
(NR: 0–20 ng/mL). Mean survival time was 24.63 ±
20.01 months (range: 1–120 months).Hepatic resection group
The HR group included 20 patients (35.1% of the
total)—18 males (90.0%) and 2 females (10.0%)—with
a mean age of 63.56 ± 9.87 years; all HR patients had
Child class A disease.
Their indocyanine green retention rates at 15 min
were <10% in 11 patients (55%) and >10% in 9 patients
(45%). Three patients (15%) underwent right hepatic
resection, 7 (35%) underwent bisectionectomy, 6 (30%)
underwent sectionectomy, and 4 (20%) underwent wedge
resection. No perioperative morbidity was observed and
no perioperative deaths occurred. All resections were
curative. The mean postoperative hospital stay was 9 days.
Two patients (10%) in this group underwent second hep-
atic resections because of tumor recurrence.
In the HR group, mean pre-treatment serum AFP level
was 71.07 ± 98.81 ng/mL (range: 1.3–356.0 ng/mL); mean
pre-treatment tumor size was 39.45 ± 30.25 mm (range:
2.9–115.0 mm); mean post-treatment serum AFP level
was 40.39 ± 74.99 ng/mL (range: 2.7–314.0 ng/mL); recur-
rence rate at 5 years was 62.3%; mean recurrent tumor
size was 4.69 ± 4.65 mm (range: 4–13 mm); and mean sur-
vival time was 31.8 ± 28.57 months (range: 3–120 months)
(Figure 1).
TACE group
The TACE group included 27 patients (47.4% of the
total), including 19 males (70.4%) and 8 females (29.6%)
with a mean age of 73 ± 8.43 years (range: 40–86 years);
3 were in Child class A and 24 in Child class B. In the
TACE group, mean pre-treatment serum AFP level was
345.58 ± 1175.90 ng/mL (range 2.2–6000 ng/mL); mean
pre-treatment tumor size was 33.07 ± 18.02 mm (range:
10–76 mm); and mean post-treatment serum AFP level
was 91.85 ± 143.75 ng/mL (range: 2.1–546 ng/mL). Twenty
patients (74.07%) in this group underwent second TACE
procedures because of tumor recurrence. The recurrence
rate for the TACE group at 5 years was 92.2%. Mean recur-
rent tumor size was 25.00 ± 19.28 mm (range: 5–64 mm).
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months) (Figure 1).
RFA group
The RFA group included 10 patients (17.5% of the total)
including 3 females (33.3%) and 7 males (66.7%). Their
mean age was 72.83 ± 7.01 years (range: 62–78 years); 2
patients had Child class A disease and 8 had Child class
B disease.
In the RFA group, mean pre-treatment serum AFP
level was 130.45 ± 242.65 ng/mL (range: 2.3–779 ng/mL);
mean pre-treatment tumor size was 29.42 ± 10.50 mm
(range: 17–50 mm); mean post-treatment serum AFP level
was 75.76 ± 137.99 ng/mL (range: 2.9–432 ng/mL); and
mean survival time was 23.70 ± 21.87 months (range: 1–
63 months) (Figure 1). Five patients (50%) in this group
underwent second RFAs because of tumor recurrence.
The recurrence rate for RFA patients at 5 years 73.5%.
The mean recurrent tumor size was 25.92 ± 2.98 mm
(range: 5–64 mm).
Overall results
The pre-treatment serum AFP level and tumor size,
3-month post-treatment serum AFP level, and time of
any tumor recurrence were recorded. Statistical analyses
showed significant correlations between pre-treatment
serum AFP level (AFPT0) and recurrent tumor size (RTS)
(P < 0.05) and between 3-month post-treatment AFP level
(AFPT3) and RTS (P < 0.05). We saw no significant correl-
ation between pre-treatment tumor size (TST0) and RTS
(Figure 2).
We saw no significant correlations between AFPT0,
TST0, or AFPT3 and RTS in the HR, TACE or RFA groups
(Figures 3, 4 or 5, respectively), possibly because of the
small numbers of patients in these groups. Comparisons
of survival curves using the log-rank (Mantel–Cox) test
showed that patients who underwent HR survived signifi-
cantly longer than those who underwent TACE or RFA
(both P < 0.05). Patients who underwent TACE and RFAFigure 2 Correlations between studied variables and recurrent tumor
recurrent tumor size (RTS) were significantly correlated (r = 0.329 P < 0.05). (
P > 0.05). (c) The 3-month post-treatment serum level (AFTT3) and recurrendid not significantly differ in survival times (Figure 1). Sur-
vival curves on χ2 analysis did not significantly differ.Discussion
HCC is one of the most common cancers worldwide,
and is associated with a high mortality rate. Curative
therapies such as HR or liver transplantation are feasible
in 20–40% of patients [13]. TACE and RFA are the most
commonly used treatment modalities when surgical ex-
cision is not indicated. In the present study, the rate of
patients who underwent HR is higher than the rate re-
ported in the literature. This is because only about half
of the patients with HCC treated in our department over
the study period were included in this study. If we con-
sider all the excluded patients, their HR rate is quite
similar to the rate reported in the literature [1,3,11].
Clinical studies suggest a relationship between serum
AFP level and HCC severity. Serum AFP level may thus
be useful for monitoring treatment response [14], and
has been suggested to be directly related to tumor size.
The ratio of serum AFP level to tumor diameter may be
a better predictor of recurrence after curative resection
than serum AFP level alone [10,15]. No published stud-
ies have investigated whether pre- and post-treatment
serum AFP levels predict tumor recurrence size in pa-
tients who underwent HR, TACE, and RFA. In the pre-
sent study, the variables and recurrent tumor size in the
HR, TACE and RFA groups showed a correlation be-
tween pre- and post-treatment serum AFP levels and re-
current tumor size, whereas no correlation was found
between pre-treatment tumor size and recurrent tumor
size.
Several study groups recently proposed staging systems
for HCC based on the extent of tumor and the under-
lying liver function, such as the Cancer of the Liver
Italian Program (CLIP) score (based on tumor size), serum
AFP level, Child-Pugh functional class, and portal vein
thrombosis [16].size in all patients. (a) Pre-treatment serum AFP level (AFPT0) and
b) Recurrent tumor size (TST0) and RTS were not correlated (r = 0.020,
t tumor size were significantly correlated (r = 0.312, P < 0.05).
Figure 3 Correlations between studied variables and recurrent tumor size in patients who underwent HR. (a) Pre-treatment serum AFP
level (AFPT0) and recurrent tumor size (RTS) were not correlated (r = 0.206, P > 0.05). (b) Recurrent tumor size (TST0) and RTS were not correlated
(r = 0.101, P > 0.05). (c) The 3-month post-treatment serum level (AFTT3) and RTS were not correlated (r = 0.251, P > 0.05).
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per month is a useful tool for diagnosing HCC in pa-
tients with liver cirrhosis and imaging findings that im-
ply presence of tumors, especially when the serum AFP
level is >200 ng/mL [2]. We have shown the usefulness
of serum AFP level as a diagnostic tool. However, several
factors limit its worth as a prognostic factor. Cut-off value
is critical; a much higher cut-off value (600–1000 ng/mL)
is required to predict prognosis compared with the diag-
nostic value (200–500 ng/mL). Extremely high serum AFP
(>10,000 ng/mL) predicts poor outcome (3-year survival
rate: 40%) compared with moderately elevated serum
AFP (200–10 000 ng/mL; 3-year survival rate: ~70%)
[10]. Serum AFP >1000 ng/mL is uncommon with tu-
mors measuring <2 cm in diameter, whereas AFP may rise
progressively to 1000–10,000 ng/mL as a tumor in-
creases to >5 cm in diameter.
In contrast, Peng et al. [14] reported an association be-
tween mortality rate and serum AFP level. After 2 years,
130 of 160 patients (81.25%) in their study were still alive,
with survival rates of 86.8% in patients with serum AFP
level <20 μg/L, 88.9% with serum AFP level 20–250 μg/L,
and 69.6% with serum AFP level >250 μg/L. These results
show that HCC patients with a serum AFP level of >250
μg/L had higher mortality rate than those with a serum
AFP level of ≤250 μg/L. Although we did not use a specificFigure 4 Correlations between studied variables and recurrent tumor
level (AFPT0) and recurrent tumor size (RTS) were not correlated (r = 0.371,
(r = 0.190, P > 0.05). (c) The 3-month post-treatment serum level (AFTT3) andcut-off limit in this investigation, patients with serum
AFP levels above 250 μg/L were considered to have poor
prognoses.
The role of AFP in the genesis of HCC has also been
studied. A retrospective study of 160 patients with HCC,
of whom 72 received conservative treatment and 88 un-
derwent surgical resection, and who were followed up
every 6 months for 2 years, found that high serum AFP
was associated with increased mortality in both treat-
ment groups [14]. Apparently, AFP is not only a diag-
nostic marker, but is also a growth factor that promotes
tumor progression, as supported by reports that higher
serum AFP is associated with increased mortality [14].
AFP can promote HCC cell growth [17-19]. AFP+ HCC
has higher cell proliferative activity than AFP− HCC, as
shown by the Ki-67 index [20], whereas AFP downregu-
lation can suppress HCC cell growth [21,22].
The time from HCC resection to recurrence is an in-
dependent predictor of survival after recurrence [23,24].
Early recurrence (≤1 year after hepatectomy) has a worse
prognosis than late recurrence (>1 year after hepatectomy)
[25], due to the different pathogeneses of early and late re-
currence. Large tumor size is also a risk factor for recur-
rence [25], but early recurrence is frequent even after
curative resection of a small tumor [26]. Early recurrence
after HR might result from intrahepatic metastasis fromsize in patients who underwent TACE. (a) Pre-treatment serum AFP
P > 0.05). (b) Recurrent tumor size (TST0) and RTS were not correlated
RTS were not correlated (r = 0.273, P > 0.05).
Figure 5 Correlations between studied variables and recurrent tumor size in patients who underwent RFA. (a) Pre-treatment serum AFP
level (AFPT0) and recurrent tumor size (RTS) were not correlated (r = 0.042, P > 0.05). (b) Recurrent tumor size (TST0) and RTS were not correlated
(r = 0.020, P > 0.05). (c) The 3-month post-treatment serum level (AFTT3) and RTS were not correlated (r = 0.396, P > 0.05).
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late recurrence is more likely to result from multicentric
tumor development. This might explain why some HCC
patients have AFP− primary tumors but AFP+ recurrent
tumors: these tumors probably have different cell lines,
which develop at different times. The current study found
that the recurrent tumor size was correlated with 3-month
post-treatment serum AFP level, and that survival was
correlated with tumor size and serum AFP level.
We found a significant correlation between longer sur-
vival and low pre- and post-treatment serum AFP levels.
We also found that patients who underwent HR sur-
vived longer than those who underwent TACE or RFA.
When outcomes were analyzed within treatment groups,
patients with low pre- and post-treatment serum AFP
levels and small tumor size tended to survive longer, but
not significantly so. This lack of significant correlations
is probably because of the small numbers of patients in
the treatment groups. However, the findings suggest that
further study of these relationships is warranted.
HR is the treatment of choice for HCC patients with-
out liver cirrhosis. Among patients with cirrhosis, candi-
dates for HR should be carefully selected to reduce the
risks of postoperative hepatic failure and death. The 5-
year survival rate after HR can exceed 50% [5]. However,
HR is associated with a high rate of local recurrence. In
most cases, this is thought to result from occult micro-
metastases in the remaining liver parenchyma rather
than inadequate surgical resection [27]. In the present
study, long survival rates with low recurrence rates were
due to the efforts to achieve safe oncologic margins dur-
ing surgery.
A study of 12,118 HCC patients found that tumor
diameter and serum AFP levels were predictive for pa-
tients who underwent HR, with tumors measuring <
20 mm in diameter having better prognoses than tumors
measuring 20–50 mm in diameter [28]. This is consistent
with our findings, in that patients who underwent HR
with tumors <50 mm and lower pre-and post-treatment
serum AFP levels had longer survival times.The association of serum AFP level >200 ng/mL to in-
creased risk of mortality was novel, but expected. Change
in serum AFP levels (defined as a >50% decrease com-
pared with baseline) after locoregional therapy are report-
edly useful in assessing tumor response and survival [29],
and for assessing lesions that have progressed on imaging
examinations [30].
RFA is a popular local ablative therapy for unresect-
able HCC because of its safety and efficacy, but it is as-
sociated with a very high rate of recurrence (36%) [31].
Tumor diameter >2.5 cm is reportedly a risk factor for
local recurrence [32], which may be related to the peri-
tumoral vessels having a “heat-sink” effect on intrahepa-
tic blood flow. RFA of large tumors can be technically
challenging, requiring multiple overlapping spheres of
tissue ablation under imaging guidance to ensure that
no viable malignant tissue remains [33]. A histological
study of patients who underwent liver transplantation
after RFA found residual tumor tissue in 37% of patients
with HCC ≤3 cm in diameter and 71% of patients with
HCC >3 cm in diameter. Combining RFA with TACE can
probably reduce the amount of such microscopic local
tumor tissue [34].
A study that compared RFA and TACE in treating
HCC within the Milan criteria found similar long-term
survival rates in both treatment groups, but found that
patients with smaller tumor volumes (<11 cm3) survived
longer after RFA than after TACE [35]. However, we
found no correlations between pre-treatment tumor size
or serum AFP level and outcome in our RFA patients.
The current study evaluated relationships between treat-
ment modalities and survival according to pre-treatment
tumor size, but found no significant differences between
patients who underwent TACE and those who underwent
RFA. However, we found significant association between
treatment modality and survival. Patients who underwent
HR survived longer than those treated with TACE or RFA.
Although international guidelines indicate RFA is more ef-
fective than surgery in selected patients, such as those
with small tumors [5], we found no significant differences
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cording to tumor size.
Conclusions
Our results show that serum AFP levels are useful for
diagnosing recurrence and predicting prognosis in HCC
patients who have undergone HR, RFA or TACE. HR
remains the treatment of choice for HCC in suitable
patients.
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